not been well-described to date. For ctDNA, it is unclear whether a personalized targeted assay (as has been previously described) is necessary or whether a gene panel may suffice. Here, we compared the performance of these biologically distinct assays in a cohort of metastatic patients.
evaluate the accuracy of these models with our single medical center database in Taiwan. METHODS: From 2007 to 2015, 1613 patients with pathology report of non-muscle invasive bladder urothelial carcinoma (UC) were enrolled. Patients with history of primary (pure) CIS, muscle invasive or upper tract UC were excluded. The definition of recurrence was reappearance of UC in the bladder, and progression was advancing in stage, metastasis or death caused by UC. EORTC and CUETO score have been calculated for each patient, then assigned into 4 groups. Regression model were created and obtained the concordance indexes.
RESULTS: A total of 958 patients were in the cohort, with 55-month follow-up in average. The mean age was 73 (AE12.7) years old, 835 (81.9%) male patients, 103 (10.1%) concurrent CIS, 659 (64.6%) primary occurrence and 274 (26.9%) patients received adjuvant intravesical BCG instillation. Four hundred twenty-four (44.3%) recurrence and 133 (13.9%) progression were noted. After stratification, the 5-year recurrence rate of 4 groups were 0%, 37%, 55% and 82% (EORTC, figure) , then 40%, 42%, 53% and 68% (CUETO). The 5-year progression rate were 0%, 9%, 17% and 35% (EORTC, figure) , then 4%, 7%, 14% & 26% (CUETO). All showing statistical significance. The concordance index of disease recurrence was 0.592 and 0.586 respectively for EORTC and CUETO model, showing suboptimal discrimination, while better in respect of disease progression (0.658 and 0.643, respectively).
CONCLUSIONS: In our single institute cohort and Asian population, both EORTC and CUETO model reflected the trend of outcomes. EORTC score is a better predictor but still overestimated the risk. Due to guideline migration and more intensive adjuvant treatment, a modified risk calculator for NMIBC might be warranted.
Source of Funding: none

MP05-04 PREOPERATIVE THROMBOCYTOSIS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CANCER OF THE BLADDER-AN INDEPENDENT PROGNOSTIC PARAMETER FOR AN IMPAIRED ONCOLOGICAL OUTCOME
Friedrich Jokisch*, Munich, Germany; Tobias Grimm, Munich, Germany; Alexander Buchner, Gerald Schulz, Alexander Kretschmer, Munich, Germany; Alexander Karl, Christian Stief, Munich, Germany INTRODUCTION AND OBJECTIVES: For many solid and malignant tumours thrombocytosis is associated with an impaired onclogical outcome concerning cancer specific survival (CSS).
So far there is only limited data on the prognostic relevance in patients undergoing radical cystectomy (RC) for urothelial carcinoma of the bladder (UC).
The aim of this study was to investigate the influence of an elevated platelet count (PPC) in patients undergoing RC for UC on the oncological prognosis in a large cohort of patients. Furthermore, correlation of preoperative thrombocytosis (PTC) with histo-pathological parameters and perioperative blood transfusion (PBT) rates were analyzed.
METHODS: A retrospective analysis of 866 patients undergoing RC for UC between 2004 and 2017 in a tertiary care urological department was performed. For the cohort PTC was defined as a platelet count > 400 G/l. Chi-square test and Mann-Whitney test were used to investigate the association of PTC with categorical variables (tumour stage, grade and perioperative BT parameters). Logrank test and Cox regression analyses were used to analyse the association of PTC with outcome.
RESULTS: The median age of patients at the moment of RC was 70 years, 23% were female and 77% were male. The median PPC in the cohort was 255 G/l. PTC was detected in 8% of the patients. The median follow-up was 23 months. The CSS adapted to PTC (thrombocytes:< 400 G/l vs. > 400 G/l) was 70% vs. 44% after 2 years and 55% vs. 29% after 5 years, respectively. PTC was significantly associated with muscle invasion, advanced tumour stages and nodal metastases. PTC was also significantly associated with a higher rate of PBT (52% (35/67) vs. 31% (250/799); p[<0.001). In the multivariate analysis PTC was significantly related to poor oncological survival (Hazard Ratio[2.23; p<0.001) .
CONCLUSIONS: In this study, PTC was significantly associated with impaired oncological outcome of patients undergoing RC for UC. It represents an independent prognostic parameter for patients' oncological outcome after RC and therefore can help to identify patients with poor prognosis. Intriguingly, PTC is significantly correlated to an increased rate of PBT, which can be explained through tumourassociated alterations of haemostasis.
Source of Funding: none
MP05-05 PERIVESICAL STRANDING ON PREOPERATIVE AXIAL IMAGING DOES NOT PREDICT T3 BLADDER CANCER ON FINAL PATHOLOGY
Jay Fuletra*, Matthew Kaag, Andrew Watts, Erik Lehman, Jay Raman, Suzanne Merrill, Hershey, PA INTRODUCTION AND OBJECTIVES: Staging imaging characteristics in bladder cancer (BC), such as hydronephrosis, are predictive of !pT3 disease at time of radical cystectomy (RC) and can be useful adjuncts in preoperative medical decision making. However, the predictive capacity of other imaging findings, such as perivesical stranding (PS), remains unclear. Thus, we investigated whether PS prior to transurethral resection of bladder tumor (TURBT) was associated with !pT3 BC following RC in patients who did not receive neoadjuvant chemotherapy (NAC).
METHODS: We identified 433 patients with BC who underwent RC from 2003 to 2018 of which 128 did not receive NAC. Evidence of PS on pre-TURBT imaging was determined by radiologist review and a stranding grading system (minimal/moderate/severe) was created. Wilcoxon rank sum and two-sample t-tests identified associated factors with PS. Multivariable logistic regressions were used to evaluate the capacity of PS as a reliable preoperative predictor for !pT3 BC.
RESULTS: Of the 128 patients who did not receive NAC, 48 (37.5%) had pT3 and 12 (9.4%) had pT4 BC at RC. Preoperative imaging consisted of CT in 125 (97.7%) patients and MRI in 3 (2.3%). PS
